Session 2: Parallel oral abstract sessions
Clinical & Sociobehavioural ScienceMaximazaalEpidemiology & Public HealthMauritszaalBasic & Translational ScienceRaadzaal
Chairs: Judith Branger (Flevoziekenhuis) & Casper Rokx (Erasmus MC)Chairs: Janneke van de Wijgert (UMC Utrecht) & Brooke Nichols (AIGHD)Chairs: Leanne Helgers (Amsterdam UMC) & Jéssica dos Santos (Radboudumc)
12:00 - 12:10O.01 Discontinuing PrEP, why and what next? – An exploration of why European MSM stop taking PrEP, how they continue to protect themselves from HIV and who is being left behindJohann Kolstee
(Maastricht University)
O.07 Evaluating the impact and effectiveness of HIV testing strategies among men who have sex with men in the NetherlandsAlexandra Teslya
(UMC Utrecht)
O.13 Siglec-1 functions as a sensor inducing innate and adaptive immunity to HIV-1Bart Grijmans
(Amsterdam UMC)
12:10 - 12:20O.02 Applying structural topic modelling based on machine learning to empower qualitative research: Perceptions of long-acting injectable PrEP among MSM in the Netherlands and Belgium based on Dutch open-ended responsesHaoyi Wang
(Maastricht University)
O.08 Identifying where HIV self-screening yields the greatest impact: insights from routine data in South AfricaAlexandra De Nooy
(AIGHD)
O.14 HIV-Associated Sex Differences in the Plasma Proteome Associate with Reservoir Size and CVD riskSuzanne Ruijten
(Radboudumc)
12:20 - 12:30O.03 Development, validation, and real-world implementation of a rapid diagnostic assay for the screening of non-suppressible viremia in people with HIV-1Jolanda Voermans
(Erasmus MC)
O.09 Changes in condomless anal sex and HIV and STI incidence among men who have sex with men over a period of 15 years: findings from the prospective Amsterdam Cohort StudiesCarien Blomaard
(GGD Amsterdam)
O.15 Sc-SQuHIVLa: Advancing HIV-1 Reservoir Quantification Through Single-Cell In Situ RT-LAMP Amplification and Flow Cytometric DetectionZora Sinay
(Erasmus MC)
12:30 - 12:40O.04 Nurse-directed same-day initiation of cART: high feasibility and more rapid virologic control using a uniform algorithmMaaike Kok (OLVG) O.10 HIV Prevention Pathways Among Individuals Who Discontinued PrEP at the Center for Sexual Health Amsterdam: Might They Still Benefit from PrEP?Inge Willemstein
(GGD Amsterdam)
O.16 TRIM24 acts as an HIV-1 restriction factor and is a potential target for latency reversalCharlotte Verkuijlen
(Amsterdam UMC)
12:40 - 12:50O.05 People with HIV with major ECG abnormalities have a significantly higher risk of incident CVD compared to people without HIVManon Vanbellinghen
(Amsterdam UMC)
O.11 Impact of the termination of the Dutch PrEP pilot on community pharmacy dispensing patternsPiter Oosterhof
(OLVG)
O.17 Latency Promoting Agents as Experimental Tools and Block-and-Lock Candidates in HIV Cure ResearchAnniek Tanja
(UMC Utrecht)
12:50 - 13:00O.06 Incidence of community-acquired pneumonia and herpes zoster in people with HIV based on CD4-count and age in the current antiretroviral therapy era: a longitudinal cohort study Anke Bruns
(UMC Utrecht)
O.12 Reconstructing the 2022 mpox outbreak among MSM in the Netherlands: Insights into transmission dynamics by HIV statusJacob Roberts
(UMC Utrecht)
O.18 Comparing a Nanobody-Based Anti-Capsid Biological and Lenacapavir as Intracellular Capsid Inhibitors to Block HIV-1 ReplicationFlorence Stel
(Amsterdam UMC)